# NCT04108195 (NCT04108195)

> A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04108195
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Multiple Myeloma
- Interventions: Daratumumab; Talquetamab; Teclistamab; Pomalidomide
- Enrollment: 290
- Primary outcome: Part 1: Number of Participants With Dose Limiting Toxicity (DLT)
- Primary outcome: Part 1: Number of Participants With Dose Limiting Toxicity by Severity
- Primary outcome: Part 2: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
- Primary outcome: Part 2: Number of Participants With Adverse Events and SAEs by Severity

## Indexed commentary on NCT04108195 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04108195